{ "docId": "019dd923-5de0-76bd-a164-b717ba6950ff", "docSlug": "eb4f894ec6f4abbf", "documentTitle": "Medical Affairs Outlook Report 2023", "authorId": "ZS", "authorName": "ZS", "documentKindSlug": "consulting-deck", "documentKindLabel": "Consulting deck", "sourceTypeSlug": "strategy_consulting", "sourceTypeLabel": "Strategy consulting", "presentationDate": null, "orientation": "portrait", "aspectRatio": 0.773, "pageNumber": 11, "pageCount": 17, "prevPage": 10, "nextPage": 12, "slideType": "key_takeaways", "function": "summarize", "density": "overcrowded", "nDataPoints": 7, "notes": "The slide uses a narrative structure to present findings from external respondent mentions regarding KOL information needs.", "elementsJson": [ "paragraph", "bullet_list", "headline_text" ], "metadataConfidence": 0.95, "imagePath": null, "slideHref": "/slides/019dd923-5de0-76bd-a164-b717ba6950ff/11", "deckHref": "/decks/019dd923-5de0-76bd-a164-b717ba6950ff", "deckJsonHref": "/decks/019dd923-5de0-76bd-a164-b717ba6950ff.json", "deckAnchorHref": "/decks/019dd923-5de0-76bd-a164-b717ba6950ff#slide-11", "components": [ { "bbox": { "h": 0.08, "w": 0.75, "x": 0.213, "y": 0.59 }, "kind": "callout", "text": "Relevant clinical data remains the most valuable information for KOLs throughout the product life cycle, according to nearly half of the mentions from external respondents.", "attrs": null, "subkind": "primary", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "5f014ff8-55c0-441a-876a-d1cf7e18f41f", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.32, "w": 0.73, "x": 0.233, "y": 0.24 }, "kind": "list", "text": "Phase 1: 25% of the mentions from external respondents indicated collaboration opportunities on clinical trials and research programs as the most valuable information, while 16% of mentions indicated trial objectives and future vision.\nPhase 2: Almost a quarter of the mentions from external respondents indicated the latest pipeline developments and product information as most valuable, followed by clinical trial design information at 18% of mentions.\nPhase 3: More than a quarter of the mentions from external respondents indicated clinical trial design information as most valuable, followed by the latest pipeline developments and product information at 15% of mentions. Additionally, MSLs can provide information to KOLs on congress presentations and publications during this phase, according to 5% of mentions from external respondents.\nPeri-launch and launch phase: Almost one-fifth of mentions from external respondents indicated cost effectiveness and coverage as the most valuable information, followed by latest pipeline developments and product information, according to about 15% of mentions.", "attrs": null, "subkind": "bullet", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "ad4c4f45-bffa-490e-973d-18e5e1a9e4dd", "frameworkName": null, "frameworkSlug": null }, { "bbox": null, "kind": "metric", "text": "mentions: 25%", "attrs": null, "subkind": "primary", "toolName": "Quantification", "toolSlug": "quantification", "confidence": null, "componentId": "019dd951-edaa-73b9-9029-1e3c22b14ce0", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.06, "w": 0.75, "x": 0.213, "y": 0.75 }, "kind": "paragraph", "text": "Most KOLs prefer to start engaging with MSLs prior to launch. In addition to scientific engagements, there are opportunities for medical affairs to co-create solutions and collaborate with KOLs. They can work together to create better outcomes for patients by improving patient access and accelerating trials.", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "0ef590e1-320a-466c-a396-7d2b9dc5010f", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.07, "w": 0.73, "x": 0.233, "y": 0.16 }, "kind": "paragraph", "text": "mentions indicated that relevant clinical data—which includes the mechanism of action (MOA), safety and efficacy data and more—was the most valuable piece of information. Notably, relevant clinical data is most valuable for all the KOLs who want to begin interactions with MSLs in the post-launch phase. We also found that during:", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "fc674492-7bb0-4f22-ac66-f7477271c7a2", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.03, "w": 0.45, "x": 0.213, "y": 0.71 }, "kind": "title", "text": "How KOLs and medical affairs can collaborate", "attrs": null, "subkind": "headline", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "19b1cd05-5b64-453d-ad7f-bcb82eb0f98b", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.02, "w": 0.05, "x": 0.878, "y": 0.04 }, "kind": "title", "text": "REPORT", "attrs": null, "subkind": "headline", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "c0579507-d103-45a8-ae89-314d9f03c186", "frameworkName": null, "frameworkSlug": null } ], "metrics": [], "tools": [ { "name": "Aha! Moment", "slug": "aha-moment", "agent": "Storyteller", "layer": "slide", "matchId": "ae8c85e7-17c9-4762-8608-2e492e88bd08", "evidence": "Relevant clinical data remains the most valuable information for KOLs throughout the product life cycle, according to nearly half of the mentions from external respondents.", "confidence": 0.7 } ], "frameworks": [], "arcBeats": [ { "to": 15, "from": 9, "beatId": "c525a5ef-3a99-4c51-8abc-eb5dad661dff", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Solution & Approach", "beatSlug": "consultants-gambit-solution-approach", "evidence": "The deck provides key takeaways and recommendations for medical affairs organizations, including prioritizing investments and collaborating with external stakeholders", "position": 2, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" }, { "to": 14, "from": 10, "beatId": "ddd73dd8-76c8-4866-b638-a1b59773307b", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "The deck provides data and statistics to support its recommendations, including survey results from internal and external respondents", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "loops": [ { "to": 15, "from": 6, "name": "Logic Chain", "slug": "01-logic-chain", "bestFor": "Skeptical audiences, controversial recommendations, rigorous analysis", "matchId": "fb6f3987-81f5-48cc-b7d0-39a0cd21772e", "evidence": "The deck presents a logical chain of ideas, starting with the situation overview and building towards key takeaways and recommendations", "position": 0, "objective": "Understand the engagement landscape and prioritize investments", "structure": "Premise 1 (Accepted truth) -> Premise 2 (Observed fact) -> Therefore... (Inevitable conclusion)", "confidence": 0.7, "description": "Build an airtight chain of logic where each premise leads inevitably to the conclusion" }, { "to": 15, "from": 9, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "dff223a3-dda3-48f8-a5dd-27a7371e6fe5", "evidence": "The deck implies that not prioritizing investments and adapting to changing engagement landscapes may result in missed opportunities", "position": 1, "objective": "Highlight the consequences of not adapting to changing engagement landscapes", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }